Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

Inclusion Criteria: * Is at least the legal age of consent for clinical trials when signing the ICF * Is capable of providing signed informed consent and complying with protocol requirements * Agrees to use contraceptive measures consistent with local regulations and the following: WOCBP must have a negative urine pregnancy test at baseline before receiving IMP * Has completed the qualifying efgartigimod SjD studies and agrees to continue study drug treatment without interruption in the extension study Exclusion Criteria: * Clinically significant disease (including newly diagnosed malignancy or cardiovascular disease) or intention to have surgery during the study; or any other medical condition that, in the investigator's opinion, would confound the results of the study or put the participant at undue risk * Pregnant or intention to become pregnant during the study * Any severe systemic SjD manifestation that may put the participant at undue risk based on the investigator's opinion